1. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
- Author
-
Dangas, George, Baber, Usman, Sharma, Samin, Giustino, Gennaro, Sartori, Samantha, Nicolas, Johny, Goel, Ridhima, Mehta, Shamir, Cohen, David J., Angiolillo, Dominick J., Zhang, Zhongjie, Camaj, Anton, Cao, Davide, Briguori, Carlo, Dudek, Dariusz, Escaned, Javier, Huber, Kurt, Collier, Timothy, Kornowski, Ran, Kunadian, Vijay, Moliterno, David J., Ohman, E. Magnus, Weisz, Giora, Gil, Robert, Krucoff, Mitchell W., Kaul, Upendra, Oldroyd, Keith G., Sardella, Gennaro, Shlofmitz, Richard, Witzenbichler, Bernhard, Kastrati, Adnan, Han, Ya-ling, Steg, Philippe Gabriel, Pocock, Stuart, Gibson, C. Michael, and Mehran, Roxana more...
- Subjects
Ticagrelor ,Percutaneous Coronary Intervention ,Treatment Outcome ,Clinical Research ,Humans ,Drug-Eluting Stents ,Stents ,Everolimus ,Cardiology and Cardiovascular Medicine ,Platelet Aggregation Inhibitors - Abstract
BACKGROUND: In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). AIMS: The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type. METHODS: In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation. RESULTS: Out of 5,769 patients, 3,014 (52.2%) had DP-EES, 1,350 (23.4%) had DP-ZES and 1,405 (24.4%) had BP-DES. Compared with ticagrelor plus aspirin, ticagrelor monotherapy had significantly lower BARC type 2, 3 or 5 bleeding compared with DAPT; DP-EES (3.8% vs 6.7%; HR 0.56, 95% CI: 0.41-0.78), DP-ZES (4.6% vs 6.9%; HR 0.66, 95% CI: 0.42-1.04) and BP-DES (4.2% vs 7.9%; HR 0.52, 95% CI: 0.33-0.81; p(interaction)=0.76). Ticagrelor monotherapy resulted in similar rates of death, MI, or stroke: DP-EES (4.2% vs 4.3%; HR 0.97; 95% CI: 0.68-1.37); DP-ZES (4.1% vs 3.1%; HR 1.32; 95% CI: 0.75-2.33); BP-DES (3.9% vs 4.2%; HR 0.92; 95% CI: 0.54-1.55; p(interaction)=0.60). In both unadjusted and covariate-adjusted analyses, DES type was not associated with any differences in ischaemic or bleeding complications. CONCLUSIONS: As compared with ticagrelor plus aspirin, ticagrelor monotherapy after a short DAPT duration lowered bleeding complications without increasing the ischaemic risk, irrespective of DES type. We observed no significant differences among DES types. more...
- Published
- 2022
- Full Text
- View/download PDF